Trial Profile
Comparison of Therapeutic and Adverse Effects of Leupromer (Iranian Formulated LHRH agonist) and Eligard in patients with Metastatic Prostate Cancer -
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 16 Sep 2016
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 May 2013 Recruitment complete, according to the Iranian Registry of Clinical Trials.
- 25 Jan 2013 New trial record